Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 8 years
- Director since
- 2023
8 years of board service in total across 3 boards, counting each seat separately. Longest: Aurinia Pharmaceuticals Inc, 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Context Therapeutics Inc. June 24, 202699.9%
-
Skye Bioscience Inc. May 26, 202695.1%
-
Skye Bioscience Inc. June 6, 202590.9%
-
Aurinia Pharmaceuticals Inc June 14, 202450.9%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 21, 2024 | Aurinia Pharmaceuticals Inc | Grant or award | +12,135 | — | — |
| Nov 11, 2024 | Aurinia Pharmaceuticals Inc | Open-market sale | −5,241 | $8.43 | $44,182 |
| Nov 8, 2024 | Aurinia Pharmaceuticals Inc | Option exercise | +17,913 | — | — |
Questions about Karen L. Smith
What boards is Karen L. Smith on?
Karen L. Smith sits on the boards of Aurinia Pharmaceuticals Inc, Context Therapeutics Inc. and Skye Bioscience Inc.
How long has Karen L. Smith served on boards?
Our records show at least 8 years of board service across 3 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.